# Modular Medical, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Modular Medical, Inc.). ## Overview Modular Medical, Inc. is a U.S.-based pre-revenue medical device company developing insulin pump systems for people with diabetes. Its core effort is to commercialize a low-cost, easier-to-use patch pump platform, starting with MODD1 and then a next-generation tubeless version called Pivot. ## Products & services • MODD1 insulin pump • Pivot next-generation tubeless patch pump • Diabetes pump commercialization and training support • Regulatory clearance and manufacturing transfer services - **Insulin pump devices** (0%) — Wearable insulin delivery devices designed for people requiring multiple daily insulin doses. - **Next-generation patch pump platform** (0%) — Tubeless and simplified pump designs intended to improve usability and manufacturability. - **Regulatory and commercialization activities** (0%) — FDA clearance, manufacturing transfer, and launch preparation needed to bring products to market. - MODD1 two-part patch insulin pump - Pivot tubeless patch pump with improved usability - FDA 510(k) regulatory submissions and clearance work - Manufacturing transfer to contract manufacturer - Commercial launch, training, and reimbursement support ## Customers The company targets insulin-dependent diabetes patients, especially people with type 1 diabetes and a growing type 2 population using multiple daily injections. It also sells through the healthcare channel, relying on diabetes educator practices, primary care physicians, distributors, and payors to support adoption and reimbursement. - **Type 1 diabetes patients** (primary) — Buy or are prescribed insulin pumps for continuous, wearable insulin delivery and better daily management. - **Type 2 diabetes patients on multiple daily injections** (primary) — Targeted as a larger, underpenetrated group that may adopt pumps if the device is simpler and lower cost. - **Diabetes educator practices** (secondary) — Prescribe and train patients on pump use, making them a key channel for adoption and support. - **Primary care physicians and distributors** (secondary) — Help reach daily insulin users who are not managed by specialist pump centers. - Type 1 diabetes patients needing wearable insulin delivery - Type 2 diabetes patients on multiple daily insulin injections - Diabetes educator practices that train and prescribe pumps - Primary care physicians managing daily insulin users - Distributors reaching patients outside specialist pump centers - Payors and insurers that determine reimbursement access ## Geography Modular Medical is headquartered and operates in San Diego, California, and all employees are located in the United States. The company currently focuses on the U.S. market, where it has FDA clearance for MODD1 and is preparing commercial launch, while also planning future foreign regulatory approvals. - Headquartered in San Diego, California - All employees are located in the United States - Initial commercialization focus is the U.S. market - FDA clearance obtained for U.S. marketing of MODD1 - Foreign jurisdiction approvals are a future expansion goal ## Strategy The company’s strategy is to win adoption by simplifying insulin pump use, lowering training burden, and reducing cost versus existing devices. It is also shifting toward a more manufacturable next-generation product, Pivot, while building a channel model that combines distributors with a focused direct sales effort to diabetes educator practices. - **Commercialize MODD1 and launch initial shipments** (short-term) — The company needs first product revenue and real-world adoption to validate the platform and channel strategy. - **Obtain FDA clearance for Pivot** (medium-term) — Pivot is intended to replace MODD1 with a more usable and manufacturable product. - **Build a scalable commercialization model** (medium-term) — The company is trying to expand beyond specialist pump users into a broader diabetes market. - Target the underpenetrated 'almost-pumper' patient pool - Use lower training burden to broaden clinician adoption - Leverage distributors plus a small direct sales force - Transfer manufacturing to a tier-one contract manufacturer - Advance Pivot to improve cost, usability, and manufacturability ## Risks The company is pre-revenue and depends on external financing, so execution risk and dilution risk are central. It also faces regulatory, manufacturing, reimbursement, and competitive risks typical of medical device commercialization, with larger rivals already established in insulin pumps. - **Going concern and financing dependence** [critical] — The company states substantial doubt about its ability to continue without additional capital. - **Regulatory approval and FDA compliance** [high] — Commercial launch depends on 510(k) clearance and ongoing quality-system compliance. - **Manufacturing and supply chain execution** [high] — The company must transfer production and maintain compliant contract manufacturing. - **Competitive pressure from established pump makers** [high] — Medtronic, Tandem Diabetes Care, and Insulet have larger resources and installed bases. - **Reimbursement and adoption friction** [medium] — Insurance coverage and training economics affect whether clinicians prescribe and support the device. - Going-concern risk if additional capital is not raised - Pre-revenue status means no operating cash generation yet - FDA and quality-system compliance could delay or disrupt launch - Manufacturing transfer and scale-up may create supply interruptions - Large competitors have greater resources and market presence - Reimbursement and training economics may slow adoption ## Accounting As a pre-revenue development-stage company, the main accounting focus is on R&D expense recognition, stock-based compensation, and estimates used in accruals and taxes. Investors should also watch going-concern disclosure and financing-related accounting because the company relies on equity raises to fund operations and commercialization. - **Research and development expense** — High and rising R&D can obscure underlying commercialization progress - **Stock-based compensation** — Affects operating expense and shareholder dilution - **Use of estimates and accruals** — Can move quarterly results materially - **Going-concern assessment** — Important for liquidity analysis and balance-sheet interpretation - R&D is expensed as incurred and drives reported losses - Stock-based compensation can materially affect operating expense - Accrual estimates affect reported liabilities and period costs - Going-concern disclosure signals financing uncertainty - Future commercialization may introduce revenue recognition judgments --- *Last updated: 2026-04-28T20:27:32.835937+00:00*